John G. D. Cannon

Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study

Anne Lynn S. Chang, Duy Tran, John G. D. Cannon et al. · Journal of the American Academy of Dermatology · 2018 · 116 citations · Full text

Medicine, Dermatology, Oncology +17

Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group

Alexandra G. Lopez‐Aguiar, Mohammad Y. Zaidi, Eliza W. Beal et al. · Annals of Surgical Oncology · 2019 · 44 citations · Full text

Medicine, Oncology, Surgery +14

A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery

John G. D. Cannon, Jeffery S. Russell, Jinah Kim et al. · JAAD Case Reports · 2018 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit

James R. Barrett, Victoria R. Rendell, Courtney Pokrzywa et al. · Journal of Surgical Oncology · 2020 · 35 citations · Full text

Medicine, Oncology, Surgery +13

Diagnostic staging laparoscopy in gastric cancer treatment: A cost‐effectiveness analysis

Kevin Li, John G. D. Cannon, Sam Y. Jiang et al. · Journal of Surgical Oncology · 2017 · 33 citations

Medicine, Oncology, Surgery +17